Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
SERMSearch Engine Reputation Management
SERMSelective Estrogen Receptor Modulator
SERMStructured Entity Relationship Model
SERMState Emergency and Rescue Management (Australia)
SERMSafety and Environmental Risk Management Rating Agency (London, England)
SERMSoutheastern Railway Museum (Duluth, Georgia, USA)
References in periodicals archive ?
The newer agents seem to have more potent estrogenic effects on bone than are seen with raloxifene and, at the same time, may not be associated with increased endometrial thickness or other uterine effects, a concern that developed with other SERMs that were being investigated for postmenopausal osteoporosis.
Taylor, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs.
Pharmaceutical companies are striving to produce the SERM with the ideal profile of estrogen agonist and antagonist properties for the treatment and prevention of breast cancer, osteoporosis, and cardiovascular disease.
they do not block estrogens at the receptor site as SERMs do.
The randomized trials were primarily performed by oncologists, but the application of SERM prevention falls largely on the primary care community, which cares for patients at risk for breast cancer.
SERMs that are currently approved and marketed in the United States have not been shown to have beneficial effects on vaginal tissue and none are approved for use in treating vaginal atrophy symptoms.
Pfizer submitted a new drug application to the Food and Drug Administration in 2007, and in 2008 an advisory panel voted 9-3 that the benefits of the SERM outweighed this risk in postmenopausal women with osteoporosis.
Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM.
As expected, the SERM had no effect on the rate of estrogen receptor-negative breast cancers.
A recent article discussed the unexpected adverse events reported in clinical trials of the selective estrogen-receptor modulator levormeloxifene ("Adverse Gynecologic Events Halt Research on Promising SERM," Oct.
Testing and diligence in the reception of the work entrusted by the SERM under the arrangements of ZAC in the territory of the city of Montpellier and before delivery of work to the licensing authority.